Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Protein-Tyrosine Kinases Medicine & Life Sciences
Mutation Medicine & Life Sciences
Leukemia Medicine & Life Sciences
fms-Like Tyrosine Kinase 3 Medicine & Life Sciences
4'-N-benzoylstaurosporine Medicine & Life Sciences
Cytarabine Medicine & Life Sciences
Chemotherapy Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2017

Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase–driven leukemias and other malignancies

Bruner, J. K., Ma, H. S., Li, L., Qin, A. C. R., Rudek, M. A., Jones, R. J., Levis, M. J., Pratz, K. W., Pratilas, C. A. & Small, D. Oct 15 2017 In : Cancer Research. 77, 20, p. 5554-5563 10 p.

Research output: Contribution to journalArticle

Protein-Tyrosine Kinases
Leukemia
Neoplasms
Acute Myeloid Leukemia
Mitogen-Activated Protein Kinase Kinases

Advances in targeted therapy for acute myeloid leukaemia

Kayser, S. & Levis, M. J. Jan 1 2017 (Accepted/In press) In : British Journal of Haematology.

Research output: Contribution to journalArticle

Acute Myeloid Leukemia
Drug Therapy
Therapeutics
Chromosome Aberrations
Protein-Tyrosine Kinases

A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia

Gojo, I. , Beumer, J. H. , Pratz, K. W. , McDevitt, M. A. , Baer, M. R. , Blackford, A. L. , Smith, B. D. , Gore, S. D. , Carraway, H. E. , Showel, M. M. , Levis, M. J. , Dezern, A. E. , Gladstone, D. E. , Ji, J. J. , Wang, L. , Kinders, R. J. , Pouquet, M. , Ali-Walbi, I. , Rudek, M. A. , Poh, W. & 5 others Herman, J. G., Karnitz, L. M., Kaufmann, S. H., Chen, A. & Karp, J. E. Feb 1 2017 In : Clinical Cancer Research. 23, 3, p. 697-706 10 p.

Research output: Contribution to journalArticle

temozolomide
Acute Myeloid Leukemia
Methylation
Phosphorylation
Polymers

A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia

Pratz, K. W., Rudek, M. A., Gojo, I., Litzow, M. R., McDevitt, M. A., Ji, J., Karnitz, L. M., Herman, J. G., Kinders, R. J., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M. M., Gladstone, D. E., Levis, M. J., Tsai, H. L., Rosner, G., Chen, A., Kaufmann, S. H. & Karp, J. E. Feb 15 2017 In : Clinical Cancer Research. 23, 4, p. 899-907 9 p.

Research output: Contribution to journalArticle

Leukemia, Myelomonocytic, Chronic
Topotecan
Carboplatin
Leukemia
Neoplasms

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Knapper, S., Russell, N., Gilkes, A., Hills, R. K., Gale, R. E., Cavenagh, J. D., Jones, G., Kjeldsen, L., Grunwald, M. R., Thomas, I., Konig, H., Levis, M. J. & Burnett, A. K. Mar 2 2017 In : Blood. 129, 9, p. 1143-1154 12 p.

Research output: Contribution to journalArticle

Chemotherapy
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Phosphotransferases
Drug Therapy